Medical network on July 21 - the Chinese government in the national health care system in the new 36 kinds of drugs, including blockbuster drugs from multinational pharmaceutical companies, such as roche herceptin, Johnson &johnson Velcade, new biological Revlimid and astrazeneca Brilinta.
According to the ministry of human resources and social security, the average discount for the drug is 44 per cent, with the highest discounts of up to 70 per cent.
In this batch, there were 16 types of cancer drugs. Roche is undoubtedly the biggest winner, with four drugs on the list (herceptin, avastin, rituximen and trocke). Even if not included in the Chinese medicine list, the four drugs are expected to become the world's best-selling cancer drug by 2022.
Astrazeneca was approved for three drugs: blood thinner Brilinta, breast cancer drug Faslodex and new atypical antipsychotic drug Seroquel.
GSK, Merck, novartis, bayer, j&j, novo nord and sanofi also have new products included in the list.
China implements the national health insurance plan, and the national reimbursement list of drug costs is covered by the country. China updated the list in February after eight years. Just two months later, the government said it was in talks about 44 new drugs for drugs.
The policy will greatly reduce the economic burden on patients. For drugmakers, the list of medicines included in China's health insurance would undoubtedly bring huge market expansion. On the other hand, the new discounts will lower the single profit of the drug, so the drugmakers must increase the market capacity substantially to offset the profit losses from the discounts.
Take roche's drug. Herceptin negotiated a price of 440 milligrams of 7,200 yuan per bottle ($1,066); The price of avastin is slightly less than 2,000 yuan per bottle ($296). The Rituxan100 mg unit costs 2,418 yuan ($358) and 500 milligrams for about 8,290 yuan ($1,227).
According to some Chinese patient community information on the Internet, herceptin currently sells for about 22, 000 yuan to 25, 000 yuan, and is unable to access health care. But that's not the official number.
The introduction of innovative targeted cancer drugs will further improve the availability and affordability of innovative treatments, roche said in a statement. Roche has been actively working with the national government, and the company will continue to work with local governments, medical institutions and other agencies to support the implementation of the new national reimbursement drug list.
An average of 44 percent is considered reasonable. In the talks, GSK's Viread was asked to cut prices by as much as two-thirds.
There are eight kinds of drugs is not included in the approved list, the reason is that included in the list, the increase of the market capacity to reduce discounts cannot offset the loss of profit, such as Actelion (now Johnson &johnson) pulmonary hypertension drugs Tracleer and immunology of Janssen Remicade.
Faced with imminent threat of generic drugs, Actelion has lowered Tracleer last year's price in China, from 56 grain of 19980 yuan ($2960) to 2960 yuan ($590), while the company also said unbearable to a 44% cut. |
